New iPSC kits deliver rapid neural cell differentiation

Amsbio has expanded its range of iPSC Differentiation Kits, offering faster and more flexible generation of specific neural cell types without compromising cell purity or reproducibility.

The new Quick-Glia™ product line features human induced pluripotent stem cell (iPSC)-derived glial cells designed to support rapid and reliable research in neurobiology, drug discovery and neurodegenerative disease modelling. The kits provide a scalable and standardised workflow, enabling conversion of iPSCs into functional neural cells in approximately 1–2 weeks. Designed for ease of use, they support applications including disease modelling, compound screening and broader neuroscience research.

The Quick-Glia™ Astrocyte – SeV kits enable differentiation of human pluripotent stem cells into astrocytes using Sendai virus technology in a streamlined and reproducible process. These kits are designed to generate highly pure astrocyte populations with minimal variability. Astrocytes are increasingly recognised as active regulators of brain function, making robust and well-characterised in vitro models essential for research. Confirmation of identity and purity using established astrocyte markers is key to ensuring experimental reliability.

The range also includes Quick-Glia™ human iPSC-derived microglia, supplied as high-purity, cryopreserved cells. These ready-to-use microglia mature rapidly and provide a consistent in vitro model for studying human microglial biology, neuroinflammation and neurodegenerative disease mechanisms. They are suited to applications such as drug discovery, toxicity screening and disease modelling. A dedicated microglia maintenance medium is also available separately to support optimal culture performance.

By offering standardised, off-the-shelf differentiation solutions, the Quick-Glia™ range helps reduce variability and improve reproducibility in neuroscience research, while simplifying complex iPSC workflows.

More information online